. 2007 Apr 18;98(6):779–789. doi: 10.1111/j.1349-7006.2007.00477.x

Table 2.

Summary of studies in which pharmacokinetic parameters of TFT (± TPI) were determined

Study (model)	TFT treatment	Pharmacokinetic parameters				Reference
Study (model)	TFT treatment	C_max(µg/mL)	T_max(min)	T_1/2(min)	AUC (µg h/mL)	Reference
Dexter et al. (1972) (human)	27 mg/kg i.v.			18		⁽ ²³ ⁾
Takeda et al. (1992) (mouse)	50 mg/kg oral	8	30	30	7	⁽ ²⁴ ⁾
Fukushima et al. (2000)(monkey) (mouse)	10 mg/kg oral (+ equi‐M TPI)	0.23 (15)	60 (60)	?	0.28 (28)	⁽ ³⁴ ⁾
Fukushima et al. (2000)(monkey) (mouse)	50 mg/kg oral (+ equi‐M TPI)	16 (32)	10 (30)	?	13 (24)
Yano et al. (2004) (mouse)	50 mg/kg oral TFT alone	13	30	?	8	⁽ 32, 33 ⁾
Hong et al. (2006) (human) (human)	50 mg/m²/d TAS‐102 (MTD)	9.1	30		15.9	⁽ ⁷⁵ ⁾
Hong et al. (2006) (human) (human)	100 mg/m²/d TAS‐102 (DLT)	13.1	45		27.8

AUC, area under the plasma concentration time curve; DLT, dose‐limiting toxicity; MTD, maximum‐tolerated dose; TFT, thymidine analog trifluorothymidine; TPI, thymidine phosphorylase inhibitor.